Prometheus Biosciences, Inc.
Prometheus Biosciences, Inc. (RXDX) Stock Competitors & Peer Comparison
See (RXDX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RXDX | $199.92 | +0.09% | 9.6B | -56.47 | -$3.54 | N/A |
| VRTX | $451.76 | +5.10% | 110.4B | 25.83 | $16.85 | N/A |
| REGN | $718.54 | +0.51% | 73.4B | 17.39 | $40.96 | +0.51% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $824.21 | +5.37% | 50.3B | 36.10 | $22.53 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $294.08 | -0.33% | 38B | 71.57 | $3.98 | N/A |
| RVMD | $141.92 | +0.07% | 30.6B | -20.27 | -$7.11 | N/A |
| UTHR | $576.99 | +2.13% | 24.2B | 21.06 | $27.06 | N/A |
| BNTX | $93.52 | -0.64% | 23.6B | -15.66 | -$5.96 | N/A |
Stock Comparison
RXDX vs VRTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, VRTX has a market cap of 110.4B. Regarding current trading prices, RXDX is priced at $199.92, while VRTX trades at $451.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas VRTX's P/E ratio is 25.83. In terms of profitability, RXDX's ROE is -0.31%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, RXDX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check VRTX's competition here
RXDX vs REGN Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, REGN has a market cap of 73.4B. Regarding current trading prices, RXDX is priced at $199.92, while REGN trades at $718.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas REGN's P/E ratio is 17.39. In terms of profitability, RXDX's ROE is -0.31%, compared to REGN's ROE of +0.14%. Regarding short-term risk, RXDX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check REGN's competition here
RXDX vs VRNA Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, RXDX is priced at $199.92, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas VRNA's P/E ratio is -102.80. In terms of profitability, RXDX's ROE is -0.31%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, RXDX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check VRNA's competition here
RXDX vs ARGX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ARGX has a market cap of 50.3B. Regarding current trading prices, RXDX is priced at $199.92, while ARGX trades at $824.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ARGX's P/E ratio is 36.10. In terms of profitability, RXDX's ROE is -0.31%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, RXDX is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ARGX's competition here
RXDX vs SGEN Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, RXDX is priced at $199.92, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RXDX's ROE is -0.31%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, RXDX is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check SGEN's competition here
RXDX vs ALNY Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ALNY has a market cap of 38B. Regarding current trading prices, RXDX is priced at $199.92, while ALNY trades at $294.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ALNY's P/E ratio is 71.57. In terms of profitability, RXDX's ROE is -0.31%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, RXDX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ALNY's competition here
RXDX vs RVMD Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RVMD has a market cap of 30.6B. Regarding current trading prices, RXDX is priced at $199.92, while RVMD trades at $141.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RVMD's P/E ratio is -20.27. In terms of profitability, RXDX's ROE is -0.31%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, RXDX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RVMD's competition here
RXDX vs UTHR Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, UTHR has a market cap of 24.2B. Regarding current trading prices, RXDX is priced at $199.92, while UTHR trades at $576.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas UTHR's P/E ratio is 21.06. In terms of profitability, RXDX's ROE is -0.31%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RXDX is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check UTHR's competition here
RXDX vs BNTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BNTX has a market cap of 23.6B. Regarding current trading prices, RXDX is priced at $199.92, while BNTX trades at $93.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BNTX's P/E ratio is -15.66. In terms of profitability, RXDX's ROE is -0.31%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, RXDX is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BNTX's competition here
RXDX vs INSM Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, INSM has a market cap of 22.5B. Regarding current trading prices, RXDX is priced at $199.92, while INSM trades at $113.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas INSM's P/E ratio is -18.04. In terms of profitability, RXDX's ROE is -0.31%, compared to INSM's ROE of -1.30%. Regarding short-term risk, RXDX is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check INSM's competition here
RXDX vs RPRX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RPRX has a market cap of 22.2B. Regarding current trading prices, RXDX is priced at $199.92, while RPRX trades at $51.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RPRX's P/E ratio is 27.18. In terms of profitability, RXDX's ROE is -0.31%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, RXDX is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RPRX's competition here
RXDX vs MRNA Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MRNA has a market cap of 21B. Regarding current trading prices, RXDX is priced at $199.92, while MRNA trades at $53.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MRNA's P/E ratio is -6.50. In terms of profitability, RXDX's ROE is -0.31%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, RXDX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MRNA's competition here
RXDX vs ROIV Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ROIV has a market cap of 20.7B. Regarding current trading prices, RXDX is priced at $199.92, while ROIV trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ROIV's P/E ratio is -24.75. In terms of profitability, RXDX's ROE is -0.31%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, RXDX is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ROIV's competition here
RXDX vs BGNE Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, RXDX is priced at $199.92, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RXDX's ROE is -0.31%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, RXDX is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BGNE's competition here
RXDX vs INCY Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, INCY has a market cap of 20B. Regarding current trading prices, RXDX is priced at $199.92, while INCY trades at $100.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas INCY's P/E ratio is 14.17. In terms of profitability, RXDX's ROE is -0.31%, compared to INCY's ROE of +0.29%. Regarding short-term risk, RXDX is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check INCY's competition here
RXDX vs DNA-WT Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, RXDX is priced at $199.92, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RXDX's ROE is -0.31%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, RXDX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check DNA-WT's competition here
RXDX vs GMAB Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, GMAB has a market cap of 16.1B. Regarding current trading prices, RXDX is priced at $199.92, while GMAB trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas GMAB's P/E ratio is 19.83. In terms of profitability, RXDX's ROE is -0.31%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, RXDX is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check GMAB's competition here
RXDX vs ASND Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, RXDX is priced at $199.92, while ASND trades at $239.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ASND's P/E ratio is 26.82. In terms of profitability, RXDX's ROE is -0.31%, compared to ASND's ROE of -56.42%. Regarding short-term risk, RXDX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ASND's competition here
RXDX vs SMMT Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SMMT has a market cap of 14.5B. Regarding current trading prices, RXDX is priced at $199.92, while SMMT trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SMMT's P/E ratio is -11.74. In terms of profitability, RXDX's ROE is -0.31%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, RXDX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check SMMT's competition here
RXDX vs JAZZ Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, JAZZ has a market cap of 14B. Regarding current trading prices, RXDX is priced at $199.92, while JAZZ trades at $224.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas JAZZ's P/E ratio is 2032.82. In terms of profitability, RXDX's ROE is -0.31%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, RXDX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check JAZZ's competition here
RXDX vs BBIO Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, RXDX is priced at $199.92, while BBIO trades at $64.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BBIO's P/E ratio is -17.29. In terms of profitability, RXDX's ROE is -0.31%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, RXDX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BBIO's competition here
RXDX vs KRTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, RXDX is priced at $199.92, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RXDX's ROE is -0.31%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, RXDX is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check KRTX's competition here
RXDX vs EXEL Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, EXEL has a market cap of 12.5B. Regarding current trading prices, RXDX is priced at $199.92, while EXEL trades at $49.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas EXEL's P/E ratio is 16.46. In terms of profitability, RXDX's ROE is -0.31%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, RXDX is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check EXEL's competition here
RXDX vs IONS Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, IONS has a market cap of 12.5B. Regarding current trading prices, RXDX is priced at $199.92, while IONS trades at $76.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas IONS's P/E ratio is -37.50. In terms of profitability, RXDX's ROE is -0.31%, compared to IONS's ROE of -0.59%. Regarding short-term risk, RXDX is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check IONS's competition here
RXDX vs MDGL Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, RXDX is priced at $199.92, while MDGL trades at $497.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MDGL's P/E ratio is -36.90. In terms of profitability, RXDX's ROE is -0.31%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, RXDX is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MDGL's competition here
RXDX vs RNAM Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, RXDX is priced at $199.92, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RNAM's P/E ratio is -17.39. In terms of profitability, RXDX's ROE is -0.31%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, RXDX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check RNAM's competition here
RXDX vs AXSM Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, AXSM has a market cap of 11.1B. Regarding current trading prices, RXDX is priced at $199.92, while AXSM trades at $222.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas AXSM's P/E ratio is -58.19. In terms of profitability, RXDX's ROE is -0.31%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, RXDX is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check AXSM's competition here
RXDX vs ARWR Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ARWR has a market cap of 11B. Regarding current trading prices, RXDX is priced at $199.92, while ARWR trades at $77.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ARWR's P/E ratio is -34.25. In terms of profitability, RXDX's ROE is -0.31%, compared to ARWR's ROE of -0.56%. Regarding short-term risk, RXDX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ARWR's competition here
RXDX vs BMRN Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BMRN has a market cap of 10.2B. Regarding current trading prices, RXDX is priced at $199.92, while BMRN trades at $52.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BMRN's P/E ratio is 37.83. In terms of profitability, RXDX's ROE is -0.31%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, RXDX is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BMRN's competition here
RXDX vs CYTK Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CYTK has a market cap of 9.3B. Regarding current trading prices, RXDX is priced at $199.92, while CYTK trades at $74.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CYTK's P/E ratio is -10.88. In terms of profitability, RXDX's ROE is -0.31%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, RXDX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CYTK's competition here
RXDX vs KRYS Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, RXDX is priced at $199.92, while KRYS trades at $309.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas KRYS's P/E ratio is 41.94. In terms of profitability, RXDX's ROE is -0.31%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, RXDX is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check KRYS's competition here
RXDX vs IMGN Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, RXDX is priced at $199.92, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RXDX's ROE is -0.31%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, RXDX is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check IMGN's competition here
RXDX vs IBRX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, IBRX has a market cap of 8.5B. Regarding current trading prices, RXDX is priced at $199.92, while IBRX trades at $8.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas IBRX's P/E ratio is -9.54. In terms of profitability, RXDX's ROE is -0.31%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, RXDX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check IBRX's competition here
RXDX vs BPMC Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, RXDX is priced at $199.92, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BPMC's P/E ratio is -51.58. In terms of profitability, RXDX's ROE is -0.31%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, RXDX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check BPMC's competition here
RXDX vs CERE Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, RXDX is priced at $199.92, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CERE's P/E ratio is -16.47. In terms of profitability, RXDX's ROE is -0.31%, compared to CERE's ROE of -0.72%. Regarding short-term risk, RXDX is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CERE's competition here
RXDX vs ABVX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, RXDX is priced at $199.92, while ABVX trades at $121.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ABVX's P/E ratio is -21.54. In terms of profitability, RXDX's ROE is -0.31%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, RXDX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ABVX's competition here
RXDX vs HALO Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, RXDX is priced at $199.92, while HALO trades at $72.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas HALO's P/E ratio is 25.94. In terms of profitability, RXDX's ROE is -0.31%, compared to HALO's ROE of +0.93%. Regarding short-term risk, RXDX is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check HALO's competition here
RXDX vs PCVX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, RXDX is priced at $199.92, while PCVX trades at $53.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas PCVX's P/E ratio is -7.84. In terms of profitability, RXDX's ROE is -0.31%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, RXDX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check PCVX's competition here
RXDX vs NUVL Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, RXDX is priced at $199.92, while NUVL trades at $102.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas NUVL's P/E ratio is -17.25. In terms of profitability, RXDX's ROE is -0.31%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, RXDX is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check NUVL's competition here
RXDX vs MTSR Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, RXDX is priced at $199.92, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MTSR's P/E ratio is -23.58. In terms of profitability, RXDX's ROE is -0.31%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, RXDX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MTSR's competition here
RXDX vs TECH Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TECH has a market cap of 7.4B. Regarding current trading prices, RXDX is priced at $199.92, while TECH trades at $47.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TECH's P/E ratio is 67.74. In terms of profitability, RXDX's ROE is -0.31%, compared to TECH's ROE of +0.05%. Regarding short-term risk, RXDX is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TECH's competition here
RXDX vs PRAX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, RXDX is priced at $199.92, while PRAX trades at $323.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas PRAX's P/E ratio is -24.76. In terms of profitability, RXDX's ROE is -0.31%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, RXDX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check PRAX's competition here
RXDX vs KYMR Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, RXDX is priced at $199.92, while KYMR trades at $82.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas KYMR's P/E ratio is -23.49. In terms of profitability, RXDX's ROE is -0.31%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, RXDX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check KYMR's competition here
RXDX vs MRUS Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, RXDX is priced at $199.92, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MRUS's P/E ratio is -17.05. In terms of profitability, RXDX's ROE is -0.31%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, RXDX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check MRUS's competition here
RXDX vs ACLX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, RXDX is priced at $199.92, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ACLX's P/E ratio is -28.27. In terms of profitability, RXDX's ROE is -0.31%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, RXDX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check ACLX's competition here
RXDX vs PTGX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, PTGX has a market cap of 6.7B. Regarding current trading prices, RXDX is priced at $199.92, while PTGX trades at $100.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas PTGX's P/E ratio is -57.18. In terms of profitability, RXDX's ROE is -0.31%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, RXDX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check PTGX's competition here
RXDX vs TGTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TGTX has a market cap of 6.6B. Regarding current trading prices, RXDX is priced at $199.92, while TGTX trades at $43.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TGTX's P/E ratio is 15.08. In terms of profitability, RXDX's ROE is -0.31%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, RXDX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TGTX's competition here
RXDX vs RETA Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, RXDX is priced at $199.92, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RETA's P/E ratio is -66.29. In terms of profitability, RXDX's ROE is -0.31%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RXDX is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RETA's competition here
RXDX vs PTCT Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, PTCT has a market cap of 6.4B. Regarding current trading prices, RXDX is priced at $199.92, while PTCT trades at $74.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas PTCT's P/E ratio is -30.26. In terms of profitability, RXDX's ROE is -0.31%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, RXDX is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check PTCT's competition here
RXDX vs CNTA Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, RXDX is priced at $199.92, while CNTA trades at $39.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CNTA's P/E ratio is -22.24. In terms of profitability, RXDX's ROE is -0.31%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, RXDX is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CNTA's competition here
RXDX vs BLTE Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, RXDX is priced at $199.92, while BLTE trades at $154.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BLTE's P/E ratio is -65.79. In terms of profitability, RXDX's ROE is -0.31%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, RXDX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BLTE's competition here
RXDX vs CELC Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CELC has a market cap of 6.1B. Regarding current trading prices, RXDX is priced at $199.92, while CELC trades at $122.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CELC's P/E ratio is -33.15. In terms of profitability, RXDX's ROE is -0.31%, compared to CELC's ROE of -2.03%. Regarding short-term risk, RXDX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CELC's competition here
RXDX vs RYTM Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, RXDX is priced at $199.92, while RYTM trades at $89.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RYTM's P/E ratio is -27.99. In terms of profitability, RXDX's ROE is -0.31%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, RXDX is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RYTM's competition here
RXDX vs IMVT Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, RXDX is priced at $199.92, while IMVT trades at $28.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas IMVT's P/E ratio is -10.88. In terms of profitability, RXDX's ROE is -0.31%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, RXDX is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check IMVT's competition here
RXDX vs ALKS Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ALKS has a market cap of 5.9B. Regarding current trading prices, RXDX is priced at $199.92, while ALKS trades at $37.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ALKS's P/E ratio is 39.41. In terms of profitability, RXDX's ROE is -0.31%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, RXDX is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ALKS's competition here
RXDX vs CGON Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, RXDX is priced at $199.92, while CGON trades at $69.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CGON's P/E ratio is -29.62. In terms of profitability, RXDX's ROE is -0.31%, compared to CGON's ROE of -0.23%. Regarding short-term risk, RXDX is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CGON's competition here
RXDX vs COGT Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, RXDX is priced at $199.92, while COGT trades at $34.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas COGT's P/E ratio is -15.71. In terms of profitability, RXDX's ROE is -0.31%, compared to COGT's ROE of -0.83%. Regarding short-term risk, RXDX is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check COGT's competition here
RXDX vs SRRK Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, RXDX is priced at $199.92, while SRRK trades at $48.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SRRK's P/E ratio is -14.01. In terms of profitability, RXDX's ROE is -0.31%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, RXDX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check SRRK's competition here
RXDX vs CDTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, RXDX is priced at $199.92, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CDTX's P/E ratio is -19.77. In terms of profitability, RXDX's ROE is -0.31%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, RXDX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check CDTX's competition here
RXDX vs ABCM Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, RXDX is priced at $199.92, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RXDX's ROE is -0.31%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RXDX is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ABCM's competition here
RXDX vs ISEE Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, RXDX is priced at $199.92, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RXDX's ROE is -0.31%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RXDX is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ISEE's competition here
RXDX vs CORT Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CORT has a market cap of 5.5B. Regarding current trading prices, RXDX is priced at $199.92, while CORT trades at $50.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CORT's P/E ratio is 146.29. In terms of profitability, RXDX's ROE is -0.31%, compared to CORT's ROE of +0.08%. Regarding short-term risk, RXDX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CORT's competition here
RXDX vs MIRM Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MIRM has a market cap of 5.3B. Regarding current trading prices, RXDX is priced at $199.92, while MIRM trades at $104.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MIRM's P/E ratio is -7.81. In terms of profitability, RXDX's ROE is -0.31%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, RXDX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MIRM's competition here
RXDX vs APLS Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, RXDX is priced at $199.92, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas APLS's P/E ratio is 38.34. In terms of profitability, RXDX's ROE is -0.31%, compared to APLS's ROE of +0.40%. Regarding short-term risk, RXDX is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check APLS's competition here
RXDX vs APGE Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, APGE has a market cap of 5.2B. Regarding current trading prices, RXDX is priced at $199.92, while APGE trades at $82.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas APGE's P/E ratio is -20.05. In terms of profitability, RXDX's ROE is -0.31%, compared to APGE's ROE of -0.24%. Regarding short-term risk, RXDX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check APGE's competition here
RXDX vs CRSP Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, RXDX is priced at $199.92, while CRSP trades at $52.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CRSP's P/E ratio is -8.75. In terms of profitability, RXDX's ROE is -0.31%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, RXDX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CRSP's competition here
RXDX vs FBIOX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, RXDX is priced at $199.92, while FBIOX trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas FBIOX's P/E ratio is N/A. In terms of profitability, RXDX's ROE is -0.31%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, RXDX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check FBIOX's competition here
RXDX vs TERN Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, RXDX is priced at $199.92, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TERN's P/E ratio is -51.41. In terms of profitability, RXDX's ROE is -0.31%, compared to TERN's ROE of -0.20%. Regarding short-term risk, RXDX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check TERN's competition here
RXDX vs LEGN Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, LEGN has a market cap of 4.7B. Regarding current trading prices, RXDX is priced at $199.92, while LEGN trades at $26.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas LEGN's P/E ratio is -15.79. In terms of profitability, RXDX's ROE is -0.31%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, RXDX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check LEGN's competition here
RXDX vs LQDA Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, LQDA has a market cap of 4.7B. Regarding current trading prices, RXDX is priced at $199.92, while LQDA trades at $53.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas LQDA's P/E ratio is -66.41. In terms of profitability, RXDX's ROE is -0.31%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, RXDX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check LQDA's competition here
RXDX vs NAMS Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, NAMS has a market cap of 4.6B. Regarding current trading prices, RXDX is priced at $199.92, while NAMS trades at $39.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas NAMS's P/E ratio is -22.24. In terms of profitability, RXDX's ROE is -0.31%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, RXDX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check NAMS's competition here
RXDX vs SYRE Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SYRE has a market cap of 4.6B. Regarding current trading prices, RXDX is priced at $199.92, while SYRE trades at $73.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SYRE's P/E ratio is -36.05. In terms of profitability, RXDX's ROE is -0.31%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, RXDX is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check SYRE's competition here
RXDX vs FOLD Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, RXDX is priced at $199.92, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas FOLD's P/E ratio is -161.00. In terms of profitability, RXDX's ROE is -0.31%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, RXDX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check FOLD's competition here
RXDX vs CAI Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CAI has a market cap of 4.5B. Regarding current trading prices, RXDX is priced at $199.92, while CAI trades at $16.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CAI's P/E ratio is -5.65. In terms of profitability, RXDX's ROE is -0.31%, compared to CAI's ROE of +0.06%. Regarding short-term risk, RXDX is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CAI's competition here
RXDX vs AKRO Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, RXDX is priced at $199.92, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas AKRO's P/E ratio is -14.57. In terms of profitability, RXDX's ROE is -0.31%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, RXDX is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check AKRO's competition here
RXDX vs MANE Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, RXDX is priced at $199.92, while MANE trades at $106.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MANE's P/E ratio is -45.56. In terms of profitability, RXDX's ROE is -0.31%, compared to MANE's ROE of -0.76%. Regarding short-term risk, RXDX is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MANE's competition here
RXDX vs ALPN Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, RXDX is priced at $199.92, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RXDX's ROE is -0.31%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, RXDX is less volatile compared to ALPN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ALPN's competition here
RXDX vs LGND Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, LGND has a market cap of 4.4B. Regarding current trading prices, RXDX is priced at $199.92, while LGND trades at $219.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas LGND's P/E ratio is 28.78. In terms of profitability, RXDX's ROE is -0.31%, compared to LGND's ROE of +0.16%. Regarding short-term risk, RXDX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check LGND's competition here
RXDX vs XENE Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, RXDX is priced at $199.92, while XENE trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas XENE's P/E ratio is -11.87. In terms of profitability, RXDX's ROE is -0.31%, compared to XENE's ROE of -0.49%. Regarding short-term risk, RXDX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check XENE's competition here
RXDX vs KNSA Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, KNSA has a market cap of 4.4B. Regarding current trading prices, RXDX is priced at $199.92, while KNSA trades at $58.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas KNSA's P/E ratio is 64.14. In terms of profitability, RXDX's ROE is -0.31%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, RXDX is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check KNSA's competition here
RXDX vs OPT Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, RXDX is priced at $199.92, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas OPT's P/E ratio is -1.52. In terms of profitability, RXDX's ROE is -0.31%, compared to OPT's ROE of +0.88%. Regarding short-term risk, RXDX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check OPT's competition here
RXDX vs MRTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, RXDX is priced at $199.92, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RXDX's ROE is -0.31%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, RXDX is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check MRTX's competition here
RXDX vs TVTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, RXDX is priced at $199.92, while TVTX trades at $42.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TVTX's P/E ratio is -87.02. In terms of profitability, RXDX's ROE is -0.31%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, RXDX is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TVTX's competition here
RXDX vs CRNX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, RXDX is priced at $199.92, while CRNX trades at $36.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CRNX's P/E ratio is -7.11. In terms of profitability, RXDX's ROE is -0.31%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, RXDX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CRNX's competition here
RXDX vs CPRX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, RXDX is priced at $199.92, while CPRX trades at $31.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CPRX's P/E ratio is 18.54. In terms of profitability, RXDX's ROE is -0.31%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, RXDX is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CPRX's competition here
RXDX vs RYZB Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, RXDX is priced at $199.92, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RXDX's ROE is -0.31%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RXDX is less volatile compared to RYZB. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check RYZB's competition here
RXDX vs ACAD Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, RXDX is priced at $199.92, while ACAD trades at $21.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ACAD's P/E ratio is 9.86. In terms of profitability, RXDX's ROE is -0.31%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, RXDX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ACAD's competition here
RXDX vs CBAY Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, RXDX is priced at $199.92, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RXDX's ROE is -0.31%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, RXDX is less volatile compared to CBAY. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check CBAY's competition here
RXDX vs EWTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, RXDX is priced at $199.92, while EWTX trades at $33.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas EWTX's P/E ratio is -20.82. In terms of profitability, RXDX's ROE is -0.31%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, RXDX is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check EWTX's competition here
RXDX vs VKTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, RXDX is priced at $199.92, while VKTX trades at $30.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas VKTX's P/E ratio is -7.64. In terms of profitability, RXDX's ROE is -0.31%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, RXDX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check VKTX's competition here
RXDX vs TLX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, RXDX is priced at $199.92, while TLX trades at $10.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas TLX's P/E ratio is -541.50. In terms of profitability, RXDX's ROE is -0.31%, compared to TLX's ROE of -0.02%. Regarding short-term risk, RXDX is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check TLX's competition here
RXDX vs DNTH Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, RXDX is priced at $199.92, while DNTH trades at $86.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas DNTH's P/E ratio is -20.60. In terms of profitability, RXDX's ROE is -0.31%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, RXDX is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check DNTH's competition here
RXDX vs SWTX Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, RXDX is priced at $199.92, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas SWTX's P/E ratio is -13.78. In terms of profitability, RXDX's ROE is -0.31%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, RXDX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RXDX.Check SWTX's competition here
RXDX vs NAMSW Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, NAMSW has a market cap of 3.4B. Regarding current trading prices, RXDX is priced at $199.92, while NAMSW trades at $27.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas NAMSW's P/E ratio is N/A. In terms of profitability, RXDX's ROE is -0.31%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, RXDX is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check NAMSW's competition here
RXDX vs BEAM Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, BEAM has a market cap of 3.3B. Regarding current trading prices, RXDX is priced at $199.92, while BEAM trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas BEAM's P/E ratio is -64.80. In terms of profitability, RXDX's ROE is -0.31%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, RXDX is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check BEAM's competition here
RXDX vs ERAS Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, RXDX is priced at $199.92, while ERAS trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas ERAS's P/E ratio is -23.73. In terms of profitability, RXDX's ROE is -0.31%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, RXDX is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check ERAS's competition here
RXDX vs VCYT Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, RXDX is priced at $199.92, while VCYT trades at $39.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas VCYT's P/E ratio is 36.77. In terms of profitability, RXDX's ROE is -0.31%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, RXDX is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check VCYT's competition here
RXDX vs DNLI Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, RXDX is priced at $199.92, while DNLI trades at $19.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas DNLI's P/E ratio is -6.83. In terms of profitability, RXDX's ROE is -0.31%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, RXDX is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check DNLI's competition here
RXDX vs DYN Comparison May 2026
RXDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RXDX stands at 9.6B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, RXDX is priced at $199.92, while DYN trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RXDX currently has a P/E ratio of -56.47, whereas DYN's P/E ratio is -5.32. In terms of profitability, RXDX's ROE is -0.31%, compared to DYN's ROE of -0.58%. Regarding short-term risk, RXDX is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for RXDX.Check DYN's competition here